Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02226640 · ClinicalTrials.gov registry record
Uncovering the 'ORIGINS' of Diabetes
A clinical trial, sponsored by AdventHealth Translational Research Institute.
- Completed
- Registry status
- 80
- Enrollment target
NCT02226640: Completed study, sponsored by AdventHealth Translational Research Institute.
NCT02226640 is a clinical trial that has completed, run by AdventHealth Translational Research Institute. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02226640 has completed, sponsored by AdventHealth Translational Research Institute.
- COMPLETED
- Registry status
- 80 participants
- Enrollment target
Study Summary
This is a study to identify different subtypes of type 2 diabetes. The investigators will look for information at the molecular level, which may lead to personalized diagnosis and therapies.
Primary Outcome
Phenotyping will include whole body composition (DEXA), substrate metabolism, classic diabetes phenotypes, and detailed molecular phenotyping of circulating mononuclear cells/ plasma, muscle and adipose tissue.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2010-11 |
| Est. Completion | 2014-06 |
What the finished NCT02226640 record still lists
NCT02226640 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02226640 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02226640 about?
NCT02226640 is a clinical study titled "Uncovering the 'ORIGINS' of Diabetes". This is a study to identify different subtypes of type 2 diabetes. The investigators will look for information at the molecular level, which may lead to personalized diagnosis and therapies.
What is the current status of trial NCT02226640?
This trial is currently completed. The enrollment target is 80 participants. The study started on 2010-11. Estimated completion is 2014-06.
Who is sponsoring clinical trial NCT02226640?
This trial is sponsored by AdventHealth Translational Research Institute, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia